KKR & Co. completed its $5.89 billion acquisition of Integer Holdings in August 2026, the largest healthcare private equity transaction to close that month and the third-largest medtech buyout year-to-date. The deal values Integer at 13.2x trailing EBITDA, a 180 basis point premium to the sector median and 240 basis points above the valuation floor set during the Federal Reserve's tightening cycle that ended in Q2 2025. Integer manufactures cardiac rhythm management devices, neuromodulation components, and portable medical electronics across 29 facilities in nine countries, with $1.49 billion in trailing twelve-month revenue as of June 2026.

The transaction structure combined $2.1 billion in equity from KKR's North America Fund XIII and its Healthcare Strategic Growth Fund II, $3.2 billion in senior secured term loans arranged by Goldman Sachs and JPMorgan, and $590 million in subordinated notes placed with three insurance affiliates. Integer's existing management team, led by CEO Joseph Flanagan, rolled $140 million in equity and remains in place. The close followed a 14-month negotiation that began in June 2025 when Integer's board initiated a formal sale process after rejecting two unsolicited bids from Advent International and a consortium led by Bain Capital. KKR's final offer in May 2026 included a $285 million reverse breakup fee and agreed to assume Integer's $720 million in outstanding convertible notes due 2028 without restructuring.

Healthcare private equity saw $18.3 billion in completed transactions in August, representing 41% of global PE deal volume for the month, the highest sector concentration since March 2022. The Integer close accounted for 32% of that total. Medtech in particular has become the preferred subsector for large buyouts: four of the seven healthcare PE deals above $2 billion closed in 2026 have been device manufacturers or adjacent suppliers, compared to one pharmaceutical services company and two specialty pharmacy rollups. This marks a reversal from 2023-2024, when regulatory scrutiny of pharmacy benefit managers and hospital staffing platforms pushed capital toward lower-profile targets. The Integer acquisition resets the valuation benchmark for scaled medtech platforms with recurring consumables revenue and diversified customer concentration, a profile that applies to 19 publicly traded companies in the Russell 3000 with market caps between $3 billion and $12 billion.

Allocators should watch for two follow-on events. First, KKR is expected to merge Integer with its existing portfolio company Viant Medical, a smaller precision components manufacturer acquired in September 2024 for an undisclosed amount, creating a combined entity with estimated pro forma revenue of $2.1 billion and EBITDA of $480 million. That integration is expected to close by December 2026 and would position the combined platform as the second-largest independent medtech component supplier globally, behind only TE Connectivity's medical division. Second, three other PE-backed medtech platforms—Avanos Medical Devices (owned by H.I.G. Capital), Natus Medical (owned by Archimed), and AngioDynamics (public but under activist pressure from Engaged Capital)—are expected to launch sale processes before year-end, with banker mandates anticipated in October. Those processes will test whether the Integer valuation represents a new sector floor or an outlier driven by KKR's specific operational synergies.

Integer's trailing cash conversion cycle of 74 days and gross margin of 28.3% sit in the 62nd percentile for specialty medical manufacturers, making the deal less about distressed opportunity and more about scale consolidation in a fragmented supply chain. KKR paid for operational leverage, not a turnaround.